The neutral assessment of intracellular therapies (ITCI) in the UBS Group was confirmed

The UBS Group maintained its neutral recommendation for the company’s shares Intracellular Therapies (NASDAQ:ITCI – Free Report) in a research report published Tuesday, Benzinga reports. The company currently has a $83.00 price target on shares of this biopharmaceutical company, down from the previous price target of $85.00.

Several other analysts have also recently published reports on the company. Goldman Sachs Group increased their price target on Intracellular Therapies from $67.00 to $77.00 and gave the company a Neutral rating in a report on Wednesday, April 17th. Royal Bank of Canada maintained an “outperform” rating and announced a $103.00 price target for Intra-Cellular Therapies shares in a report on Tuesday. Robert W. Baird increased their price target on Intracellular Therapies from $83.00 to $103.00 and gave the company an outperform rating in a research note on Wednesday, April 17th. Needham & Company LLC increased their price target on Intracellular Therapies from $90.00 to $94.00 and gave the company a “buy” rating in a research note on Tuesday, June 18. Finally, Canaccord Genuity Group increased their price target on Intracellular Therapies from $107.00 to $113.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. Three investment analysts rated the company’s shares with a hold rating, and ten of them issued a buy rating. According to MarketBeat data, Intracellular Therapy currently has an average rating of Moderate Buy and an average price target of $94.33.

Read our latest report on intracellular therapies

Intracellular therapy stocks fell 4.2%

Shares of Intra-Cellular Therapies opened at $72.42 on Tuesday. Intracellular Therapies has a fifty-two week low of $45.50 and a fifty-two week high of $84.89. The company has a market capitalization of $7.65 billion, a PE ratio of -62.43 and a beta of 0.98. The company’s fifty-day moving average is $69.60 and its two-hundred-day moving average is $68.93.

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) released its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.15. The company’s revenue for the quarter was $144.90 million, compared to analyst estimates of $141.41 million. Intracellular therapies generated a negative return on equity of 18.49% and a negative net margin of 21.57%. The company’s revenue for the quarter increased by 52.0% compared to the same quarter last year. In the same quarter last year, the company saw EPS ($0.46). Equity research analysts predict that intracellular therapy will post -0.51 EPS for the current year.

Confidential activity in intracellular therapies

In other Intra-Cellular Therapies news, Director Rory B. Riggs sold 4,462 shares of Intra-Cellular Therapies stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $75.57 for a total value of $337,193.34. Following the completion of the sale, the director now directly owns 116,600 shares of the company’s stock valued at $8,811,462. The transaction was disclosed in a filing with the Securities and Exchange Commission, available at this hyperlink. In other intracellular therapeutics news, Nostrand CEO Robert L. Van sold 20,000 shares of the company’s stock in a transaction on Tuesday, June 18th. The shares were sold at an average price of $75.91 for a total value of $1,518,200.00. Following the sale, the director now owns 9,690 shares of the company’s stock, valued at approximately $735,567.90. The sale was disclosed in a legal filing with the Securities and Exchange Commission, available at this link. Additionally, Director Rory B. Riggs sold 4,462 shares of the company’s stock on Monday, June 24th. The shares were sold at an average price of $75.57, for a total transaction amount of $337,193.34. Following the completion of the sale, the director now directly owns 116,600 shares of the company’s stock, valued at approximately $8,811,462. The announcement of this sale can be found here. Currently, insiders own 3.40% of the shares.

Institutional investors speak out on intracellular therapies

Several large investors have recently made changes to their positions at the company. Farallon Capital Management LLC acquired new shares of stock in Intra-Cellular Therapies during the first quarter valued at approximately $15,985,000. Tidal Investments LLC increased its position in shares of Intra-Cellular Therapies by 13.9% during the first quarter. Tidal Investments LLC now owns 3,698 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 450 shares during the period. Avoro Capital Advisors LLC increased its position in shares of Intra-Cellular Therapies by 9.7% during the first quarter. Avoro Capital Advisors LLC now owns 2,475,000 shares of the biopharmaceutical company’s stock valued at $171,270,000 after acquiring an additional 219,445 shares during the period. Affinity Asset Advisors LLC acquired a new stake in shares of Intra-Cellular Therapies during the first quarter valued at approximately $3,460,000. Finally, EntryPoint Capital LLC raised its position in shares of Intra-Cellular Therapies by 138.7% during the first quarter. EntryPoint Capital LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 1,259 shares during the period. Institutional investors hold 92.33% of the company’s shares.

About intracellular therapies

(Get the free report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development and commercialization of small molecule therapeutics that address medical needs primarily in neuropsychiatric and neurological disorders by acting on intracellular signaling mechanisms in the central nervous system (CNS) in the United States .

Featured Stories

Receive daily news and assessments about intracellular therapies – Enter your email address below to receive a daily concise summary of the latest news and analyst ratings for Intracellular Therapies and related companies with MarketBeat.com’s FREE daily email newsletter.